Meeting
2020 ASCO Virtual Scientific Program
Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.
Authors
Filip Janku
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX
Filip Janku , Elena Elez , Gopa Iyer , Noboru Yamamoto , Daniel Shao-Weng Tan , Anastasios Stathis , Uz M. Stammberger , Helen Evans , Abdelkader Seroutou , Anna Mais , Martin H. Schuler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Other Developmental Therapeutics
Clinical Trial Registration Number
NCT02711345
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3640)
DOI
10.1200/JCO.2020.38.15_suppl.3640
Abstract #
3640
Poster Bd #
370
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.
First Author: Filip Janku
Poster
2021 ASCO Annual Meeting
Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma: Final results from the dose-finding phase I part of the IMMU-Target trial.
First Author: Lisa Zimmer
Poster
2015 ASCO Annual Meeting
Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors.
First Author: Christian K. Kollmannsberger
Poster
2015 ASCO Annual Meeting
First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737).
First Author: Philippe L. Bedard